Synedgen, Inc.

Other

Sekos, Inc.

Bioasyst, L.l.c.

Automedx, Inc.

US Government As Represented by the Secretary of the Army

Johns Hopkins University

The General Hospital Corporation

Providence Health & Services - Oregon

Hemcon Medical Technologies, Inc.

Providence Health System—oregon

Tricol Biomedical, Inc.

Wiesmann, William P.

Townsend, Stacy

Baker, Shenda

William P Wiesmann

Shenda M Baker

Stacy M Townsend

Mary Sandra Bogucki

Loland Alex Pranger

Loland Alexander Pranger

Simon J McCarthy

Todd D Campbell

Shenda Baker

Kenton W Gregory

Protagoras N Cutchis

Adrian Urias

Ruth Baxter

Shannon Ryan

Stacy Townsend

Jill Uyeno

Dexter G Smith

Adrian F Prokop

Louis M Guzzi

Michael H Loughnane

Ziyad Duron

Jason Milne

Kristopher Jarka

Farbod Ghassemi

Earl Smith

L Alex Pranger

George P Kearney

Frederick J Pearce

Charles L Linden, Jr

Adrian Richard Urias

Stacy Marie Townsend

Shena D Baker

Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.

Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds

Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.

Methods for treatment or prevention of damage resulting from radiation, trauma or shock

Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.

Compositions and methods of use thereof

Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx.

Derivatized chitosan polymers and methods of treating vascular disorders

Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.

Methods and compositions for treating wounds utilizing chitosan compounds

Described herein are a solution, composition, and kit of poly (acetyl, arginyl) glucosamine (PAAG), methods of making the solution, and method of treating wounds with the solution, the method comprising administering to a subject an effective amount of a solution comprising PAAG, wherein the PAAG when administered topically contacts the wound, thereby treating the wound.

Compositions and methods of use for wound healing

Described herein are methods and compositions that contain a soluble polyglucosamine or polyglucosamine derivative for use in oral health. The compositions are useful for, e.g., reducing bacteria (e.g., by clumping and removing) or disrupting a biofilm in the mouth of a subject, reducing dry mouth, and reducing oral inflammation.

Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar

The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

Chitosan-derivative compounds and methods of controlling microbial populations

Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal.

Chitosan derivatives to treat animals or optimize animal health

Growing community of inventors

Washington, DC, United States of America

William P Wiesmann